ATHX earnings call for the period ending September 30, 2019.
News & Analysis: Athersys
The FDA has given the company's lead drug platform a potential leg up in development.
The stem cell pioneer announced an update with its most important collaborator.
An investment bank analyst predicts off-the-hook gains from Athersys' "off-the-shelf" stem cell treatments.